Nifuratel-SZ, 200 mg 20 pcs

Pharmacological action – antimicrobial, antiprotozoal, antifungal.

Pharmacodynamics

Nifuratel is an antimicrobial agent of nitrofuran group with antiprotozoal, antifungal and antibacterial action.

Nifuratel has high efficacy and low toxicity which leads to a wide range of its clinical use.

Highly effective against Papiliobacter and Helicobacter pylori, Gram-positive and Gram-negative microorganisms.

The spectrum of action includes: Enterococcus faecalis, Enterococcus faecium, Staphylococcus aureus, Bacillus subtilis, Escherichia coli, Shigella flexneri 2a, Shigella flexneri 6, Shigella sonnei, Salmonella typhi, Salmonella typhimurium, Salmonella enteridis, Klebsiella spp, Enterobacter spp., Serratia spp., Citrobacter spp, Morganella spp., Rettgerella spp., Pragia fontium, Budvicia aquatica, Rachnella aquatilis and Acinetobacter spp., other atypical enterobacteria, as well as protozoa (trichomonads, amebas, giardia); less active against Proteus mirabilis, Proteus vulgaris, Pseudomonas aeruginosa. It is the drug of choice for the treatment of salmonellosis, shigellosis and other acute intestinal bacterial infections.

It is active against Trichomonas vaginalis, highly active against fungi of the genus Candida.

Particularly effective against strains of Helicobacter pylori resistant to metronidazole.

Pharmacokinetics

In oral administration it is quickly absorbed from the gastrointestinal tract. It penetrates through the GEB and GPB and is excreted with breast milk. It is metabolized in the liver and muscle tissue. It is completely excreted by the kidneys (30-50% unchanged), having a strong antibacterial effect in the urinary tract.

Indications

Active ingredient

Composition

1 tablet contains:

the active substance:

nifuratel – 200 mg;

excipients: corn starch – 90.7 mg, gelatin -2.3 mg, polyethylene glycol 6000 (macrogol) – 15.0 mg, talc – 9.0 mg; magnesium stearate – 3.0 mg;

Shell composition: Hypromellose – 5.37 mg, polysorbate-80 (tween-80) – 1.50 mg, talc – 1.50 mg, titanium dioxide E 171 – 1.13 mg, aluminum varnish based on quinoline yellow dye – 0.50 mg.

How to take, the dosage

Orally, following the recommendations.

Vaginal infections

Adults: 1 tablet 3 times a day after meals for 7 days (both sexual partners should take the drug).

Children over 3 years of age and over 20 kg body weight. The recommended dose is 10 mg/kg daily for 10 days. The recommended dose should be taken in two doses.

Urinary tract infections

Adults: depending on the severity of the disease, 1-2 tablets 3 times daily for 7-14 days.

Children over 3 years of age and with a body weight of more than 20 kg: the recommended dose is 30-60 mg/kg. The recommended dose should be taken in two doses.

The treatment of urinary tract infections may be prolonged or repeated if recommended by a physician.

Intestinal amoebiasis

Adults: 2 tablets 2-3 times a day for 10 days.

Children over 3 years of age and with a body weight greater than 20 kg: recommended dose of 10 mg/kg 3 times a day.

Lambliosis

Adults: 2 tablets 2-3 times a day for 7 days.

Children over 3 years of age and with body weight over 20 kg: recommended dose of 15 mg/kg 2 times a day for 7 days.

Inflammatory diseases of the upper gastrointestinal tract associated with Helicobacter pylori

Adults: 2 tablets 2-3 times a day for 7 days.

Children over 3 years of age and over 20 kg of body weight: Recommended dose is 15 mg/kg 2 times a day for 7 days.

Interaction

Special Instructions

When treating vaginal infections with oral therapy with Nifuratel-SZ alone, it is recommended to increase the daily dosage of the drug to 4-6 tablets.
During treatment, one should refrain from sexual intercourse.

The drug does not influence the ability to drive vehicles and to perform potentially dangerous activities requiring increased concentration and rapid psychomotor reaction.

Synopsis

Contraindications

Side effects

Overdose

Pregnancy use

Pregnancy

Nufuratel has no teratogenic effect when administered orally in preclinical studies in mice, rats and rabbits.

There are no clinical studies in pregnant women. It is not recommended to use the drug during pregnancy. The drug should only be administered under the supervision of a physician after careful evaluation of the benefits compared to the possible risks.

Nifuratel penetrates the GPB, so the drug may be used only with strict indications if the expected effect of therapy for the mother exceeds the potential risk to the fetus. If pregnancy is suspected, it is recommended to consult a physician.

Breast-feeding

Nifuratel is excreted into the breast milk, so if the drug must be prescribed while breast-feeding, the question of stopping breast-feeding should be addressed.

Similarities